CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenue:
Genetic testing	$ 420,333	$ 483,363
Other	67,233	4,030
Total revenue	487,566	487,393
Cost of revenue	394,771	383,571
Gross profit	92,795	103,822
Operating expenses:
Research and development	209,176	160,380
Selling, general and administrative	1,526,606	1,002,172
Amortization of intangibles	23,525	28,863
Total operating expenses	1,759,307	1,191,415
Loss from operations	(1,666,512)	(1,087,593)
Other income (expense):
Interest income	1,993	739
Interest expense	0	(114,726)
Total other income (expense)	1,993	(113,987)
Loss before income taxes	(1,664,519)	(1,201,580)
Benefit for income taxes	0	0
Net loss	$ (1,664,519)	$ (1,201,580)
Basic and diluted net loss per common share	$ (0.01)	$ (0.03)
Weighted average common shares outstanding, basic and diluted	122,481,674	36,775,504